Recon: Top EU court favors Illumina over EU regulators in Grail deal; US will still pay more for drugs than its peers after Medicare price negotiations

Recon

ReconJason Scott

Biologics/ biosimilars/ vaccinesHealth technology assessment (HTA)Medical DevicesPharmaceuticalsRegulatory Intelligence/PolicyReimbursement